Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Accured Expenses: 2023-2025

Historic Change in Accured Expenses for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $4.2 million.

  • Monte Rosa Therapeutics' Change in Accured Expenses rose 80.08% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 58.45%. This contributed to the annual value of $4.2 million for FY2024, which is 17.63% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Change in Accured Expenses of $4.2 million as of Q3 2025, which was up 269.73% from -$2.5 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Change in Accured Expenses' 5-year high stood at $4.2 million during Q3 2025, with a 5-year trough of -$3.9 million in Q1 2024.
  • Over the past 3 years, Monte Rosa Therapeutics' median Change in Accured Expenses value was $2.0 million (recorded in 2024), while the average stood at $623,455.
  • In the last 5 years, Monte Rosa Therapeutics' Change in Accured Expenses soared by 186.81% in 2024 and then slumped by 220.89% in 2025.
  • Monte Rosa Therapeutics' Change in Accured Expenses (Quarterly) stood at $1.3 million in 2023, then skyrocketed by 186.81% to $3.7 million in 2024, then surged by 80.08% to $4.2 million in 2025.
  • Its Change in Accured Expenses was $4.2 million in Q3 2025, compared to -$2.5 million in Q2 2025 and -$2.6 million in Q1 2025.